Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma.
作者： Xiaolei Guan , Ping Wang , Jingwei Chi , Shihua Zhao , Fei Wang
DOI: 10.1016/J.BBRC.2017.03.117
关键词:
摘要: A poor papillary thyroid cancer (PTC) prognosis is strongly associated with the BRAF V600E mutation. During tumor progression, levels of high mobility group box 1 (HMGB1) protein are often dysregulated. Results herein demonstrate that HMGB1 differ between and adjacent non-tumor tissue mRNA were higher in wild-type PTC tissues than (2-△Ct 0.31 ± 0.25 vs. 0.16 ± 0.12; P < 0.05). also differed same manner (wild-type 0.11 ± 0.04 0.03 ± 0.03; P < 0.001). Although not detected peripheral blood, low significantly related to cell lymph node metastasis extra-glandular infiltration (P = 0.045 P = 0.002). Experimental results at cellular level consistent further verified relationship HMGB1. These findings mutation down-regulates HMGB1, likely through activation mitogen-activated kinase (MAPK) signaling pathways.
sci-hub.se 参考文章(31)
Tania Pilli, Kanteti V. Prasad, Shankar Jayarama, Furio Pacini, Bellur S. Prabhakar, Potential Utility and Limitations of Thyroid Cancer Cell Lines as Models for Studying Thyroid Cancer Thyroid. ,vol. 19, pp. 1333- 1342 ,(2009) , 10.1089/THY.2009.0195
Anne M Strohecker, Eileen White, Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving mitochondrial metabolism. Autophagy. ,vol. 10, pp. 384- 385 ,(2014) , 10.4161/AUTO.27320
R Kang, D Tang, N E Schapiro, T Loux, K M Livesey, T R Billiar, H Wang, B Van Houten, M T Lotze, H J Zeh, The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics Oncogene. ,vol. 33, pp. 567- 577 ,(2014) , 10.1038/ONC.2012.631
Tetsuo Kondo, Shereen Ezzat, Sylvia L. Asa, Pathogenetic mechanisms in thyroid follicular-cell neoplasia Nature Reviews Cancer. ,vol. 6, pp. 292- 306 ,(2006) , 10.1038/NRC1836
Mingzhao Xing, Ali S. Alzahrani, Kathryn A. Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R. Michael Tuttle, Eyal Robenshtok, James A. Fagin, Efisio Puxeddu, Laura Fugazzola, Agnieszka Czarniecka, Barbara Jarzab, Christine J. O’Neill, Mark S. Sywak, Alfred K. Lam, Garcilaso Riesco-Eizaguirre, Pilar Santisteban, Hirotaka Nakayama, Ralph P. Tufano, Sara I. Pai, Martha A. Zeiger, William H. Westra, Douglas P. Clark, Roderick Clifton-Bligh, David Sidransky, Paul W. Ladenson, Vlasta Sykorova, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer JAMA. ,vol. 309, pp. 1493- 1501 ,(2013) , 10.1001/JAMA.2013.3190
Mingzhao Xing, Molecular pathogenesis and mechanisms of thyroid cancer Nature Reviews Cancer. ,vol. 13, pp. 184- 199 ,(2013) , 10.1038/NRC3431
L Liu, M Yang, R Kang, Z Wang, Y Zhao, Y Yu, M Xie, X Yin, K M Livesey, M T Lotze, D Tang, L Cao, HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells Leukemia. ,vol. 25, pp. 23- 31 ,(2011) , 10.1038/LEU.2010.225
Michiko Matsuse, Norisato Mitsutake, Susumu Tanimura, Tomoo Ogi, Eijun Nishihara, Mitsuyoshi Hirokawa, Cesar S Fuziwara, Vladimir A Saenko, Keiji Suzuki, Akira Miyauchi, Shunichi Yamashita, None, Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma. International Journal of Cancer. ,vol. 132, pp. 738- 743 ,(2013) , 10.1002/IJC.27709
Joanna Xing, Ruixin Liu, Mingzhao Xing, Barry Trink, The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochemical and Biophysical Research Communications. ,vol. 404, pp. 958- 962 ,(2011) , 10.1016/J.BBRC.2010.12.088
Kam-Tsun Tang, Chen-Hsen Lee, BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications Journal of the Chinese Medical Association. ,vol. 73, pp. 113- 128 ,(2010) , 10.1016/S1726-4901(10)70025-3